Publications by authors named "Elisabeth Arndt"
Article Synopsis
- The pharmaceutical industry is heavily involved in shaping medical knowledge and guidelines, which has led to a significant expansion in diabetes drug prescriptions, creating a billion-dollar market, particularly for type 2 diabetes and prediabetes.
- Despite claims of promoting public health, these industry-influenced guidelines are based on weak evidence and potentially harmful side effects of the recommended medications.
- The text calls for a reevaluation of the normalization of pharmaceutical industry conflicts of interest, urging for a deeper understanding of their systemic influence on medical practices and the potential long-term costs to public health.
Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent degradation of incretin hormones (glucagon-like peptide 1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]), whereas metformin may increase GLP-1 levels. We examined, in a four-period crossover trial, the influence of metformin (2,000 mg/day), sitagliptin (100 mg/day), or their combination, on GLP-1 responses and on the incretin effect in 20 patients with type 2 diabetes, comparing an oral glucose challenge (75 g, day 5) and an "isoglycemic" intravenous glucose infusion (day 6). Fasting total GLP-1 was significantly increased by metformin and not changed by sitagliptin.
View Article and Find Full Text PDF